[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].

摘要: The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively. 20 treated FOLFIRI at our hospital between October 2003 November 2005. objective overall response rate was 28% (5/18; 95% confidence interval, 9.7-54%). disease control (CR+PR+SD) 61%. most frequent grade 3 to 4 adverse event neutropenia, it seen 50%. Non-hematological toxicities mild. median survival time 11 months. 1-year 34%. This study showed the activity practice.